Jagsonpal Pharmaceuticals Share Price

223.50-6.41 (-2.79%)

Closed
As On: 25 Jun, 2026, 03:47 PM IST
As On: 25 Jun, 2026, 03:46 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	229.93
High	235.35
Low	219.87
Prev Close	229.91
Volume	1,96,360
VWAP(₹)	227.35

Share Price	Value
Today/Current/Last	223.50222.75
Previous Day	229.91230.10

Jagsonpal Pharm Share Recommendations

Recent Recos

Target₹47
OrganizationNirmal Bang Securities
BUY

View all Stock Recommendations

News & Analysis

Dividend alert: Cochin Shipyard, GRSE among over 80 stocks in focus as they approach record date
News
Sensex falls! But these stocks are up over 10% on BSE
News
Ace investor Mukul Agrawal sells shares worth Rs 1 crore in this smallcap stock. Check details
News
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcements

View all Jagsonpal Pharm Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	67.37	75.92	77.49	78.44	61.33
Total Income Growth (%)	-11.26	-2.03	-1.20	27.89	-19.67
Total Expenses	55.36	61.14	60.42	63.75	52.36
Total Expenses Growth (%)	-9.45	1.20	-5.23	21.75	39.93
EBIT	12.01	14.78	17.08	14.69	8.97
EBIT Growth (%)	-18.74	-13.45	16.28	63.77	-76.96
Profit after Tax (PAT)	8.76	10.95	12.57	10.80	6.58
PAT Growth (%)	-19.99	-12.91	16.48	63.98	-79.42
EBIT Margin (%)	17.82	19.47	22.03	18.72	14.62
Net Profit Margin (%)	13.01	14.42	16.23	13.76	10.73
Basic EPS (₹)	1.25	1.67	1.88	1.60	0.98

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	299.22	276.91	217.98	242.45	229.43
Total Revenue Growth (%)	8.06	27.03	-10.09	5.67	19.29
Total Expenses	239.62	226.73	188.11	204.18	202.11
Total Expenses Growth (%)	5.68	20.53	-7.87	1.02	18.56
Profit after Tax (PAT)	43.08	55.36	22.46	26.72	19.59
PAT Growth (%)	-22.18	146.45	-15.94	36.42	14.82
Operating Profit Margin (%)	21.10	19.02	14.70	16.34	12.20
Net Profit Margin (%)	14.99	20.60	10.76	11.28	8.66
Basic EPS (₹)	6.40	8.26	8.49	10.20	7.48

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 24.63% towards employee cost in the year ending Mar 31, 2026. (Source: Standalone Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	316.68	278.26	217.08	194.95	168.45
Total Assets Growth (%)	13.81	28.18	11.35	15.73	2.59
Total Liabilities	40.51	38.31	29.68	36.06	37.60
Total Liabilities Growth (%)	5.74	29.08	-17.69	-4.10	-11.05
Total Equity	276.17	239.95	187.40	158.89	130.86
Total Equity Growth (%)	15.09	28.04	17.94	21.42	7.32
Current Ratio (x)	5.06	6.22	10.42	5.97	3.24
Total Debt to Equity (x)	0.00	0.00	0.00	0.00	0.00
Contingent Liabilities	0.00	15.46	11.22	6.09	5.87

All figures in Rs Cr, unless mentioned otherwise

Insights

Zero Debt Burden
Company has no debt since last 5 years. (Source: Standalone Financials)

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	46.81	55.30	35.17	46.66	5.60
Net Cash used in Investing Activities	-35.65	-45.15	-24.55	-57.67	-26.21
Net Cash flow from Financing Activities	-12.15	-11.70	-8.91	-0.46	-12.30
Net Cash Flow	-0.99	-1.55	1.71	-11.47	-32.91
Closing Cash & Cash Equivalent	10.04	11.22	12.76	11.05	26.03
Closing Cash & Cash Equivalent Growth (%)	-10.46	-12.11	15.44	-57.54	-55.84
Total Debt/ CFO (x)	0.00	0.00	0.00	0.00	0.00

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 35.65 cr for investing activities which is an YoY decrease of 21.04%. (Source: Standalone Financials)

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	15.59	23.11	11.98	16.81	15.92
Return on Capital Employed (%)	21.02	20.26	15.50	23.10	20.55
Return on Assets (%)	13.60	19.89	10.34	13.70	11.62
Interest Coverage Ratio (x)	68.16	61.86	39.74	96.57	102.18
Asset Turnover Ratio (x)	0.97	1.08	1.01	1.30	1.36
Price to Earnings (x)	28.74	25.91	33.00	28.49	42.02
Price to Book (x)	4.47	5.99	3.95	4.78	6.68
EV/EBITDA (x)	16.10	22.02	18.30	16.17	27.31
EBITDA Margin (%)	24.39	22.05	15.49	16.84	12.88

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Jagsonpal Pharm	34.00	5.30	15.59	21.02	13.60	7.19	21.10	14.99	6.40	5.06	0.00	0.00
NGL Fine Chem	38.45	5.61	14.61	17.15	8.82	21.81	13.54	9.60	77.90	1.84	0.33	2.50
Ind-Swift Labs	42.12	1.26	2.99	4.33	2.47	-17.67	9.58	6.44	4.95	3.83	0.01	-0.28
Amrutanjan Health Care	26.82	12.33	16.77	23.87	13.07	9.58	13.83	9.43	14.47	3.46	0.02	0.00
Syncom Form	17.08	3.15	18.41	23.76	14.31	29.31	20.90	15.62	0.81	3.18	0.00	0.03
Add More

Annual Ratios (%)

Choose from Peers

Lincoln Pharma
Fermenta Biotech
Themis Medicare
Bajaj Healthcare
Wanbury Ltd

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Jagsonpal Pharm Stock Performance	-2.79	7.83	13.74	28.93	7.15	60.95	468.99
NGL Fine Chem Stock Performance	-2.73	31.62	32.41	27.42	132.57	96.68	0.00
Ind-Swift Labs Stock Performance	3.65	49.25	39.57	41.59	179.26	188.24	141.18
Amrutanjan Health Care Stock Performance	0.32	-6.37	-5.35	-12.81	-24.74	-10.29	-28.46
Syncom Form Stock Performance	-0.36	0.58	1.76	5.87	-30.58	113.69	0.00
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	4,54,58,210	67.89 %	0.50
Pledge	0	0.00 %	0.00
FII	16,35,064	2.44 %	0.31
DII	1,48,480	0.22 %	0.07
MF	808	0.00 %	0.00
Others	1,97,20,496	29.45 %	-0.88

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	67.89	67.39	67.54	67.65
Pledge	0.00	0.00	0.00	0.00
FII	2.44	2.12	2.12	2.17
DII	0.22	0.15	0.08	0.05
Mutual Funds	0.00	0.00	0.00	0.00
Others	29.45	30.33	30.25	30.12

Mutual Funds Ownership

MF Ownership as on 31 May 2026

Motilal Oswal BSE Healthcare ETF-G
Equity: Sectoral-Pharma
- 0.01
  Amount Invested (in Cr.)
- 0.03%
  % of AUM
- -9.32
  % Change (MoM basis)
Bandhan BSE Healthcare Index Direct-G
Equity: Sectoral-Pharma
- 0.01
  Amount Invested (in Cr.)
- 0.03%
  % of AUM
- 6.61
  % Change (MoM basis)

View all Mutual Fund Schemes

Corporate Actions

Recent
General Meeting
Buy Back of Shares
Apr 27, 2026
General Meeting
Buy Back of Shares
Apr 27, 2026
General Meeting
Buy Back of Shares
Apr 27, 2026

Board Meetings

Announced on	Meeting on
Apr 20, 2026	Apr 27, 2026
Audited Results & Final Dividend
Mar 09, 2026	Mar 12, 2026
Buy Back of Shares
Jan 13, 2026	Jan 21, 2026
Quarterly Results
Oct 27, 2025	Nov 03, 2025
Quarterly Results
Jul 23, 2025	Jul 26, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
May 06, 2025 Sep 12, 2025 125%
May 21, 2024 Sep 06, 2024 100%
May 23, 2023 Aug 21, 2023 100%
Oct 19, 2021 Oct 29, 2021 80%
Apr 27, 2026 - 200%
Bonus
Announced on Ex-Date
Apr 30, 2004 Jul 20, 2004
Bonus Ratio: 3 share(s) for every 1 shares held
Splits
Announced on Ex-Date
Oct 23, 2024 Jan 08, 2025
Split: Old FV5.0| New FV:2.0
Apr 30, 2004 Jul 20, 2004
Split: Old FV10.0| New FV:5.0
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Apr 27, 2026 -
Buy Back of Shares
Apr 27, 2026 -
Buy Back of Shares
Apr 27, 2026 -
Buy Back of Shares
Apr 27, 2026 -
Buy Back of Shares
Apr 27, 2026 -
Buy Back of Shares

Announced on	Ex-Date	Dividend%
May 06, 2025	Sep 12, 2025	125%
May 21, 2024	Sep 06, 2024	100%
May 23, 2023	Aug 21, 2023	100%
Oct 19, 2021	Oct 29, 2021	80%
Apr 27, 2026	-	200%

Announced on	Ex-Date
Apr 30, 2004	Jul 20, 2004
Bonus Ratio: 3 share(s) for every 1 shares held

Announced on	Ex-Date
Oct 23, 2024	Jan 08, 2025
Split: Old FV5.0\| New FV:2.0
Apr 30, 2004	Jul 20, 2004
Split: Old FV10.0\| New FV:5.0

Announced on	Meeting on
Apr 27, 2026	-
Buy Back of Shares
Apr 27, 2026	-
Buy Back of Shares
Apr 27, 2026	-
Buy Back of Shares
Apr 27, 2026	-
Buy Back of Shares
Apr 27, 2026	-
Buy Back of Shares

About Jagsonpal Pharm

Jagsonpal Pharmaceuticals Ltd., incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 1,464.80 Crore) operating in Pharmaceuticals sector.

Jagsonpal Pharmaceuticals Ltd. key Products/Revenue Segments include Formulations, Active Pharma Ingredients for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Standalone Total Income of Rs 67.37 Crore, down 11.26 % from last quarter Total Income of Rs 75.92 Crore and up 9.85 % from last year same quarter Total Income of Rs 61.33 Crore. Company has reported net profit after tax of Rs 8.76 Crore in latest quarter.

The company’s top management includes Mr.Rajpal Singh Kochhar, Mr.Harsha Raghavan, Mr.Manish Gupta, Mr.Prithipal Singh Kochhar, Mr.Debasis Bikash Nandy, Ms.Pallavi Dinodia Gupta, Ms.Radhika Madhukar Dudhat, Mr.Sachin Jain, Mr.Pratham Rawal. Company has H L Bansal & Co. as its auditors. As on 31-03-2026, the company has a total of 6.70 Crore shares outstanding.

Jagsonpal Pharm Share Price Today is Rs. 223.50. On previous day, the Jagsonpal Pharm Share Price (NSE) closed at Rs. 231.91, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 67.89% of the stake in Jagsonpal Pharm shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Jagsonpal Pharm stocks was 2.44% as compared to 2.12% in Dec 2025 with increase of 0.32%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.22% as compared to 0.15% in Dec 2025 with increase of 0.07%. Out of the total DII holdings in Jagsonpal Pharm shares 0.0% was held by mutual funds. The rest including public held is 29.45%. Jagsonpal Pharm stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Jagsonpal Pharm Dividend: Ever since 1978, Jagsonpal Pharm dividends has been paid out around 29 times. As on 25 Jun, 2026, 03:47 PM IST, The overall dividend yield for Jagsonpal Pharm stands at 1.72%. The last dividend paid was on September 12, 2025 (Rs. 2.5). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 6.57.

Jagsonpal Pharm Bonus: The most recent bonus issue had been in year July 20, 2004 around 21 years ago at 1 : 3 ratio. The first bonus issue was announced in Apr 2004.

Stock Forecast:
After showing 67.37 Cr. of sales and 11.26% of quarterly net loss, there have been multiple ups and downs in the Jagsonpal Pharm stock prices in the past few weeks. For example, Jagsonpal Pharm stock price on 17th of June 2026 was around Rs. 209.19. Jagsonpal Pharm share price now stands at an average of Rs. 223.50. Judging by last week's performance, stock is in up trend.

Jagsonpal Pharm has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Jagsonpal Pharm share.

Historical Prices and Performance:
Jagsonpal Pharm, incorporated in 1978 is a Small Cap company (with a market cap of Rs. 1506.81) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Jagsonpal Pharm stock was 15.59%, 23.11%, 11.98%, 16.81% and 15.92% respectively.
The Jagsonpal Pharm share gave a 3 year return of 53.23% as compared to Nifty 50 which gave a return of 28.7%.
Jagsonpal Pharm announced 125.0% final dividend on September 12, 2025.

Key Metrics:
PE Ratio of Jagsonpal Pharm is 35.28
Prices/Sales Ratio of Jagsonpal Pharm is 4.3
Price/Book Ratio of Jagsonpal Pharm is 5.5

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Jagsonpal Pharm, major competitors and peers include NGL Fine Chem, Ind-Swift Labs, Amrutanjan Health Care and Syncom Form. As of Dec 2025, the dividend yield of Jagsonpal Pharm stands at 1.72% while NGL Fine Chem, Ind-Swift Labs, Amrutanjan Health Care and Syncom Form stand at 0.06%, 0.0%, 0.91% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 35.28 and 5.5 respectively.

Leadership of Jagsonpal Pharm :
Pratham Rawal is Co. Secretary & Compl. Officer
Sachin Jain is Chief Financial Officer
Rajpal Singh Kochhar is Chairman Emeritus
Harsha Raghavan is Chairman & Non-Exe.Director
Manish Gupta is Managing Director
Prithipal Singh Kochhar is Non Executive Director
Debasis Bikash Nandy is Independent Director
Radhika Madhukar Dudhat is Independent Director
Pallavi Dinodia Gupta is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

BSE Healthcare, BSE AllCap

Address

Innov8 3rd Floor,Plot No. 211, Okhla Phase � III,New Delhi, Delhi - 110020

Contact

cs@jagsonpal.com

http://www.jagsonpal.com

PE Ratio(x)	34.00
EPS - TTM(₹)	6.57
MCap(₹ Cr.)	1,464.80
MCap Rank	85
PB Ratio(x)	5.46
Div Yield(%)	1.79
Face Value(₹)	2.00
52W High(₹)	301.65
52W Low(₹)	155.00
MCap/Sales	4.30
Beta(1 Month)	1.10
BV/Share(₹)	42.14

PE Ratio(x)	33.89
EPS - TTM(₹)	6.57
MCap(₹ Cr.)	1,459.88
MCap Rank	84
PB Ratio(x)	5.42
Div Yield(%)	1.80
Face Value(₹)	2.00
52W High(₹)	301.80
52W Low(₹)	154.90
MCap/Sales	4.30
Beta(1 Month)	1.51
BV/Share(₹)	42.14

1 Day	-2.79%
1 Month	8.66%
3 Months	21.24%
1 Year	1.26%
3 Years	48.96%
5 Years	256.8%

1 Day	-3.19%
1 Month	8.55%
3 Months	20.76%
1 Year	0.66%
3 Years	48.62%
5 Years	256.29%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Jagsonpal Pharmaceuticals Share Price

Key Metrics

Jagsonpal Pharm share price insights

Jagsonpal Pharm Share Price Returns

Jagsonpal Pharm Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Motilal Oswal BSE Healthcare ETF-G

Bandhan BSE Healthcare Index Direct-G

Jagsonpal Pharm Top Searches

Corporate Actions

About Jagsonpal Pharm

Executive Leadership

Auditors

FAQs about Jagsonpal Pharm share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News